These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 393526)

  • 1. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
    Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
    J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostanoids and hemostasis in chickens: anti-aggregating activity of prostaglandins E1 and E2, but not of prostacyclin and prostaglandin D2.
    Bult H; Wechsung E; Houvenaghel A; Herman AG
    Prostaglandins; 1981 Jun; 21(6):1045-58. PubMed ID: 7027319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC; Ebert CD; Kim SW
    Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandins as inhibitors of human platelet aggregation.
    Di Minno G; Silver MJ; de Gaetano G
    Br J Haematol; 1979 Dec; 43(4):637-47. PubMed ID: 393296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractoriness of diabetic platelets to inhibitory prostaglandins.
    Lagarde M; Berciaud P; Burtin M; Dechavanne M
    Prostaglandins Med; 1981 Oct; 7(4):341-7. PubMed ID: 6273957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet preservation during cardiopulmonary bypass (CPB) with prostaglandin (PGE1) and prostacyclin (PGI2).
    van den Dungen JJ; Velders AJ; Karliczek GF; Homan van der Heide JN; Wildevuur CR
    Trans Am Soc Artif Intern Organs; 1980; 26():481-6. PubMed ID: 7018057
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostaglandin-related renin release from rabbit renal cortical slices.
    Spokas EG; Wong PY; McGiff JC
    Hypertension; 1982; 4(3 Pt 2):96-100. PubMed ID: 7040243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of some pharmacological actions of prostaglandin E1, 6-oxo-PGE1 and PGI2.
    Adaikan PG; Tai NY; Lau LC; Karim SM; Kottegoda SR
    Prostaglandins; 1984 Apr; 27(4):505-16. PubMed ID: 6203140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes.
    Rao GH; Reddy KR; White JG
    Prostaglandins Med; 1980 Jun; 4(6):385-97. PubMed ID: 6251492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.